Wealth Enhancement Advisory Services LLC Has $1.78 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Wealth Enhancement Advisory Services LLC raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 56.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,454 shares of the biopharmaceutical company’s stock after purchasing an additional 2,323 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Alnylam Pharmaceuticals were worth $1,775,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its holdings in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 143 shares during the period. Ashton Thomas Private Wealth LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $26,000. Altitude Crest Partners Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $30,000. Friedenthal Financial acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $51,000. Finally, Meeder Asset Management Inc. increased its position in Alnylam Pharmaceuticals by 1,237.5% during the second quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 297 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares of the company’s stock, valued at $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 2.7 %

Shares of ALNY opened at $273.91 on Monday. The stock’s fifty day simple moving average is $274.61 and its 200-day simple moving average is $226.42. The firm has a market capitalization of $35.16 billion, a PE ratio of -104.55 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period last year, the company posted $1.15 EPS. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% compared to the same quarter last year. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.74 EPS for the current year.

Analyst Ratings Changes

ALNY has been the topic of several research reports. Wells Fargo & Company boosted their price objective on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. HC Wainwright reissued a “buy” rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 18th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $198.00 to $370.00 in a research note on Friday, August 16th. Finally, TD Cowen lifted their target price on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Six investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $294.50.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.